Recent Updates
Recently added Catalysts
GH Positive Sentiment

PRECISION Study Published in ESMO Open Highlights Utility of Guardant360® Liquid and Guardant Reveal® to Assess Recurrence Risk After Surgery for Colorectal Cancer Metastases

Tuesday, November 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Guardant Health announced the publication of the PRECISION study in ESMO Open, which assessed recurrence risk in colorectal cancer patients post-surgery. The study involved 130 patients and utilized blood-based genomic profiling methods. Results indicate the potential of these approaches in monitoring recurrence risk effectively.

Market Sentiment Analysis

POSITIVE FACTORS

  • Study published in a reputable journal.
  • Evaluated innovative blood-based approaches.
  • Involved 130 patients in a multicenter study.
  • Focused on colorectal cancer metastases.

Full Press Release Details

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that ESMO Open has published results from PRECISION, a prospective multicenter observational study in Japan that enrolled 130 patients and evaluated complementary blood-based approaches for assessing recurrence risk in patients undergoing curative-intent surgery for colorectal cancer metastases. The study paired pretreatment comprehensive genomic profiling (CGP) using Gu

Frequently Asked Questions

What is the PRECISION study?

The PRECISION study evaluates blood-based approaches for assessing recurrence risk in colorectal cancer.

How many patients were enrolled in the study?

The study enrolled 130 patients undergoing surgery for colorectal cancer metastases.

Where was the PRECISION study conducted?

The study was conducted in multiple centers across Japan.

What methods were used in the PRECISION study?

The study utilized comprehensive genomic profiling and blood-based assessments.

ShareAdd on Google
Tags: GH Guardant Health PRECISION study colorectal cancer recurrence risk genomic profiling
Last updated: Nov 10, 2026

Biotech snapshot

Cash runway
$1027M liquidity · $8M/mo burn
~130 mo
Minimal dilution risk